He will be effective in his new role from 1 January 2018.
Steve Beller has experience in the US neuro-stimulation market where he was most recently Area Vice-President at Abbott Neuromodulation, managing a team of over 170 people in the Western half of the US. Prior to this, Mr. Beller held Senior Director and Regional Sales Director roles at St Jude Medical Neuromodulation, before it was acquired by Abbott.
Beller will lead commercialisation efforts for Nexstim’s NBT system in the US across indications, starting with depression, following the recently announced FDA clearance for use of the NBT system in the treatment of Major Depressive Disorder (MDD). The NBT system is currently in a supplementary Phase III E-FIT trial for its use in stroke rehabilitation, which is expected to complete in mid-2018, allowing Nexstim to file for FDA clearance, following which Mr. Beller would also lead commercialisation efforts for this indication. The NBT system is based on Nexstim’s navigated Transcranial Magnetic Stimulation (nTMS) which allows for accurate, reproducible brain stimulation in therapy.
Commenting on the appointment, Martin Jamieson, Chairman and CEO, Nexstim Plc stated: “I am very pleased to welcome Steve Beller to the team. His experience in managing and directing sales in the neuromodulation field in the US will be invaluable as we develop our commercialisation capacity for the NBT system in the US ahead of its introduction to the market for the treatment of depression during H1 2018.”